Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05283148 · ClinicalTrials.gov registry record · NA
Sickle Cell Disease (SCD) Bone Pain Study
A NA study of Sickle Cell Disease and Osteoporosis, sponsored by University of California, Davis.
- Active
- Registry status
- NA
- Development phase
- 53
- Enrollment target
- 1
- Study location
NCT05283148: Active NA study of Sickle Cell Disease and Osteoporosis, sponsored by University of California, Davis.
NCT05283148 is a NA study of Sickle Cell Disease and Osteoporosis that is active but no longer recruiting, run by University of California, Davis. The registered enrollment target is 53 participants, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05283148, a NA study of Sickle Cell Disease and Osteoporosis, is active but no longer recruiting, sponsored by University of California, Davis.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 53 participants
- Enrollment target
- 1
- Study location
Study Summary
A prospective study to determine how low bone mineral density and/or vertebral compression fractures associate with pain in adults with sickle cell disease
Primary Outcome
Areal bone mineral density of the lumbar spine measured by dual-energy X-ray absorptiometry (DXA) scan and reported in grams per square centimeter.
Conditions Studied
Interventions
- OTHER Dual-energy X-ray absorptiometry
- OTHER Vertebral fracture analysis
- OTHER Adult Sickle Cell Quality of Life Measurement System pain impact questionnaire
Study Locations (1)
California
- UC Davis Comprehensive Cancer Center - Sacramento
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2022-11-03 |
| Est. Completion | 2026-07-31 |
| Phase | NA |
What the registry record for NCT05283148 still lists
NCT05283148 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 53 participants, a relatively small participant target, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (82% lower).
The record links to 10 conditions, with Sickle Cell Disease appearing as the primary indexed condition, and to 3 interventions - of which Dual-energy X-ray absorptiometry is the first listed.
NCT05283148 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05283148 about?
NCT05283148 is a clinical study titled "Sickle Cell Disease (SCD) Bone Pain Study". A prospective study to determine how low bone mineral density and/or vertebral compression fractures associate with pain in adults with sickle cell disease
What is the current status of trial NCT05283148?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 53 participants. The study started on 2022-11-03. Estimated completion is 2026-07-31.
What conditions does trial NCT05283148 study?
This clinical trial studies the following conditions: Sickle Cell Disease, Osteoporosis, Avascular Necrosis, Sickle Cell Anemia, Osteopenia.
What interventions are being tested in trial NCT05283148?
The interventions under investigation include: Dual-energy X-ray absorptiometry (OTHER), Vertebral fracture analysis (OTHER), Adult Sickle Cell Quality of Life Measurement System pain impact questionnaire (OTHER).
Who is sponsoring clinical trial NCT05283148?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05283148 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sickle Cell Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05283148's enrollment target sits among peer trials
53 102nd of 213 higher than 110 of 213 other Sickle Cell Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sickle Cell Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Early Life Exposures Among Children With Sickle Cell Disease
RECRUITING · NA
-
Exercise in Child Health
RECRUITING · NA
-
Sickle Cell Children's Exercise Study (SuCCESs)
RECRUITING · NA
-
Cutaneous Hydration Assessment in SCD
RECRUITING · NA
-
MULTIsite Feasibility of MUSIc Therapy to Address Quality Of Life in Sickle Cell Disease
RECRUITING · NA
-
Peer Support for Adolescents and Emerging Adults With Sickle Cell Pain
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04177004 · 53 participants · Phase 1
Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant
- NCT04199741 · 53 participants · Phase 1
PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56
- NCT04835129 · 53 participants · Phase 2
Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
- NCT04913805 · 53 participants · Phase 2
Matching Perfusion and Metabolic Activity in HFpEF
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI